Realbotix Leaps 9% as Investors Bet on Nasdaq Reverse Merger Deadline

Realbotix shares rally 9.4% as investors focus on Nasdaq listing via Onconetix merger, despite Q3 revenue drop to $354K and ongoing losses.

Investors pushed shares of Realbotix Corp. sharply higher on Thursday, with the stock climbing 9.4% to €0.1862 as attention shifted from a soft quarterly earnings report to the company's fast-approaching Nasdaq debut. The rally builds on a recovery that has lifted the equity roughly 23% above its 52-week low of €0.1518, though the shares remain deeply underwater for the year.

Quarterly Results Show Revenue Slide, But Team Expansion Continues

The robotics developer reported third-quarter revenue of $354,000 for the period ended June 30, 2026 — a notable drop from the $595,000 generated in the same quarter a year earlier. Over the first nine months of the fiscal year, sales came in at $932,000, down from $2.138 million in the prior-year period. The company posted a total loss of $1.695 million for the quarter.

Despite the shrinking top line, Realbotix has been pouring resources into its operational foundation. Its subsidiary, Realbotix LLC, significantly expanded its artificial intelligence and engineering workforce, growing from eight full-time employees last year to more than 20 today. Management discussed the results and strategic outlook during an investor webinar held in mid-August.

Hollywood Placement and Pilot Programs Drive Visibility

The company is leaning into high-profile exposure to complement its product roadmap. In early August, Realbotix announced an agreement with a streaming platform to feature one of its humanoid robots as a character in an episode of an Emmy-winning television series — a move management views as a gateway to broader cultural recognition beyond industrial applications.

Realbotix LLC generated $132,000 in revenue from robot deliveries and event support, while several pilot initiatives are underway. These include the deployment of "Optio," an AI teaching assistant, in a New York school district, alongside projects aimed at providing social support for seniors in the United Kingdom.

The company also plans to launch its new "Echo Generation 1" robot line later this year, selling directly to consumers online, with series production targeted for 2027.

Nasdaq Listing Timeline Takes Center Stage

The primary catalyst driving valuation, however, is the planned reverse merger with Onconetix, designed to secure a direct listing on the Nasdaq exchange. Media reports indicate the transaction should be completed by October 31, 2026. Under the deal's structure, parent company Realbotix Corp. is expected to hold between 75% and 90% of the combined entity, with Andrew Kiguel slated to serve as CEO.

Onconetix has confirmed Realbotix's role as the acquisition target, and the company views the Nasdaq move as a pathway to improved liquidity and a broader institutional investor base in the United States.

Market Position Remains Challenging

Thursday's advance offers some relief, but the stock still trades roughly 54% below its 52-week high of €0.4000, reached in October of last year. The company's punctual filing of its quarterly report — announced in early August — has been read by some market participants as a sign of orderly internal processes, even as the fundamental picture remains mixed. Whether the combination of the TV deal and the Nasdaq listing can sustain the current momentum is now the central question for shareholders.